Home › Research › Caregiving
Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions
Abeysinghe AADT, Deshapriya RDUS, Udawatte C.. Life sciences, 2020-06-23
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease (AD) is a neurodegenerative disorder and is identified as the most common cause for dementia. Despite huge global economic burden and the impact on the close family of the patients, there is no definitive cure and thus, improved treatment methods are of need. While memory and cognition are severely affected in AD, exact etiology is yet unknown. The β-Amyloid plaque formation and aggregation hypothesis is among the well-known hypotheses used to explain disease pathogenesis. Currently there are five Food and Drug Administration (FDA) approved drugs as treatment options. All these drugs are used for symptomatic treatment of AD. Thus, disease modifying therapies which can directly address the pathological changes in AD, are needed. Such therapies could be designed based on inhibiting key steps of pathogenesis. Currently there are novel AD drug candidates with various therapeutic mechanisms, undergoing different stages of drug development. Extensive research is being done globally to broaden understanding of the exact mechanisms involved in AD and to develop therapeutic agents that can successfully hinder the occurrence and progression of the disease. In this review, a comprehensive approach to understanding AD and suggestions to be considered in the development of therapeutics for it are presented.
What this study adds
Evidence grade: Low
This is a narrative review. This review states that there is no definitive cure for Alzheimer's disease and that the five FDA-approved drugs are all used for symptomatic treatment. It says disease-modifying therapies that directly address the pathological changes are needed, and that novel drug candidates with various mechanisms are undergoing different stages of drug development.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Abeysinghe, A. A. D. T., Deshapriya, R. D. U. S., & Udawatte, C. (2020). Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions. Life sciences. https://doi.org/10.1016/j.lfs.2020.117996
Vancouver
Abeysinghe AADT, Deshapriya RDUS, Udawatte C. Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions. Life sciences. 2020. doi:10.1016/j.lfs.2020.117996. PMID: 32585249.
BibTeX
@article{abeysinghe2020-32585249,
author = {Abeysinghe, A. A. D. T. and Deshapriya, R. D. U. S. and Udawatte, C.},
title = {{Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions}},
journal = {Life sciences},
year = {2020},
doi = {10.1016/j.lfs.2020.117996},
pmid = {32585249},
url = {https://doi.org/10.1016/j.lfs.2020.117996}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Thus, disease modifying therapies which can directly address the pathological changes in AD, are needed.
- Such therapies could be designed based on inhibiting key steps of pathogenesis.
- Currently there are novel AD drug candidates with various therapeutic mechanisms, undergoing different stages of drug development.
- Extensive research is being done globally to broaden understanding of the exact mechanisms involved in AD and to develop therapeutic agents that can successfully hinder the occurrence and progression of the disease.
- In this review, a comprehensive approach to understanding AD and suggestions to be considered in the development of therapeutics for it are presented.
Why it matters
This review states that there is no definitive cure for Alzheimer's disease and that the five FDA-approved drugs are all used for symptomatic treatment. It says disease-modifying therapies that directly address the pathological changes are needed, and that novel drug candidates with various mechanisms are undergoing different stages of drug development.
New to this subject? Start with our plain-English guide: Caregiving →
Study details
- Evidence strengthLow
How this study scored 46/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 44 of the 96 points we could judge it on, which is 46 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Life sciences) |
| Journal's citation record | 3 / 4 | Life Sciences: journal h-index 288 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 237 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 29.6 citations a year over 8 year(s) since 2020 |
| Impact for its field and year | 4 / 6 | Cited 16.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 5 other studies in this library |
| Still being cited | 3 / 4 | Cited 110 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author C. Udawatte holds only 1 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | University of Colombo: institution h-index 214 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 32585249) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 44 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 44 of the 96 points we could judge it on is 46 out of 100. |
| Total | 46 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.
Later studies that cite this one
5 studies in the alzhub library list this one in their references.
Related studies in Caregiving from nearby years
Also in Caregiving
69 studies in the library are filed under Caregiving with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Caregiving hub.